ArticleEndocrine-related cancer2026
Functional analysis of AIP variants in a cohort of neuroendocrine neoplasms.
Article in Endocrine-related cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loss-of-function (LOF) germline AIP variants are the main genetic cause of familial isolated pituitary adenoma and gigantism. A role for this defect in other neoplasms has been suggested, but remains unclear. We investigated the frequency, associated phenotypes, and in vitro functional effects of germline AIP variants in a cohort of Mexican patients with neuroendocrine neoplasms (NENs). Blood DNA samples from 101 adults (70.3% females) with isolated or syndromic NENs (50 with pituitary neuroendocrine tumors, PitNETs) were analyzed using a next generation sequencing panel. Targeted Sanger screening was carried out in additional family members and tumor samples. Missense and intronic variants were functionally assessed via cycloheximide chase assays or quantitative polymerase chain reaction plus sequence analysis of blood cDNA, as appropriate. Two rare likely benign defects (c.787 + 9C>T and p.T231M), two variants of uncertain significance (p.R106C and p.V291_L292del), one likely pathogenic (LP, p.C238Y), and one pathogenic (p.R304*) variant were found in six cases (5.9%). One individual was diagnosed with multiple gastric NENs and five carried PitNETs. Variant p.V291_L292del produced an unstable protein (P < 0.0001 for half-life curve, compared with wild type) and was reclassified to LP. Loss of heterozygosity in a gastric neuroendocrine tumor and nonsignificantly increased protein stability were observed for p.R106C. No deleterious effects were documented for c.787 + 9C>T. In conclusion, we determined the prevalence of AIP variants in a cohort of NENs and reclassified one VUS to LP. Our findings support the causal association of AIP LOF with PitNETs, but cannot rule out a role for AIP in other NENs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.